TCS, Anand Rathi Wealth, and Tata Elxsi are in focus following their Q1 FY26 earnings, while Glenmark Pharma made headlines with a $1.2 billion licensing deal with AbbVie. Birla Corporation secured a limestone block in Rajasthan, and IREDA may see action on sectoral cues. Watch for earnings momentum, strategic tie-ups, and regulatory updates to drive stock-specific moves. Track key corporate developments ahead of Friday’s session.
1 / 5Tata Consultancy Services | India’s largest software services firm reported a 6% year-on-year (YoY) rise in Q1 FY26 net profit to ₹12,760 crore, beating analyst expectations. Revenue dipped 1.6% quarter-on-quarter (QoQ) to ₹63,437 crore. EBIT stood at ₹15,514 crore with a 24.5% margin, and the board declared a ₹11/share dividend.
2 / 5Anand Rathi Wealth Ltd | The wealth management firm reported a strong Q1 performance with net profit rising 27.9% YoY to ₹93.9 crore, driven by solid growth in revenue and margins. Revenue from operations grew 15.3% to ₹274 crore, while EBITDA surged 30.1% to ₹127.7 crore, reflecting robust operational efficiency.
3 / 5Glenmark Pharmaceuticals Ltd | IGI Therapeutics, a Glenmark Pharma subsidiary, has signed an exclusive licensing agreement with AbbVie for its lead asset ISB 2001, developed using the BEAT® protein platform. IGI will receive $700 million upfront, up to $1.225 billion in milestones, and tiered royalties. AbbVie gains rights across major global markets.
4 / 5Birla Corporation Ltd | The company has been declared the ‘Preferred Bidder’ for the Tadas Limestone Block-II in Nagaur district, Rajasthan, as per a notification issued by the Directorate of Mines & Geology on July 10, 2025. The block spans 160.39 hectares, and Birla Corp secured it with the highest final price offer of 63.50%.
5 / 5Tata Elxsi | The Tata Group company has reported a muted Q1 FY26 performance, with net profit dropping 21% QoQ to ₹144.36 crore, below the expected ₹163 crore. Revenue declined 1.8% sequentially to ₹892 crore, missing Street estimates of ₹908 crore.
